Skip to main content Skip to office menu Skip to footer
Capital IconMinnesota Legislature

HF 2958

as introduced - 93rd Legislature (2023 - 2024) Posted on 03/16/2023 02:36pm

KEY: stricken = removed, old language.
underscored = added, new language.

Current Version - as introduced

Line numbers 1.1 1.2 1.3 1.4
1.5 1.6 1.7 1.8 1.9 1.10 1.11 1.12 1.13 1.14 1.15 1.16 1.17 1.18 1.19 1.20 1.21 1.22 2.1 2.2

A bill for an act
relating to opioid litigation; adding settling defendants to opioid litigation statute;
amending Minnesota Statutes 2022, section 3.757, subdivision 1.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

Section 1.

Minnesota Statutes 2022, section 3.757, subdivision 1, is amended to read:


Subdivision 1.

Definitions.

(a) For purposes of this section, the following terms have
the meanings given.

(b) "Municipality" has the meaning provided in section 466.01, subdivision 1.

(c) "Opioid litigation" means any civil litigation, demand, or settlement in lieu of litigation
alleging unlawful conduct related to the marketing, sale, or distribution of opioids in this
state or other alleged illegal actions that contributed to the excessive use of opioids.

(d) "Released claim" means any cause of action or other claim that has been released in
a statewide opioid settlement agreement, including matters identified as a released claim as
that term or a comparable term is defined in a statewide opioid settlement agreement.

(e) "Settling defendant" means Johnson & Johnson, AmerisourceBergen Corporation,
Cardinal Health, Inc., deleted text begin anddeleted text end McKesson Corporation,new text begin Teva Pharmaceuticals, Allergan plc,
CVS Health Corporation, Walgreens Boots Alliance, Inc., and Walmart, Inc.,
new text end as well as
related subsidiaries, affiliates, officers, directors, and other related entities specifically named
as a released entity in a statewide opioid settlement agreement.

(f) "Statewide opioid settlement agreement" means an agreement, including consent
judgments, assurances of discontinuance, and related agreements or documents, between
the attorney general, on behalf of the state, and a settling defendant, to provide or allocate
remuneration for conduct related to the marketing, sale, or distribution of opioids in this
state or other alleged illegal actions that contributed to the excessive use of opioids.